clinical disease landscape derived

{
  "input": {
    "type": "http",
    "method": "GET",
    "queryParams": {
      "lang": "en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)",
      "depth": "standard | deep (default: standard)",
      "condition": "Disease area — e.g. \"Parkinson Disease\" | \"Breast Cancer\" | \"NASH\" | \"Heart Failure\" | \"Schizophrenia\""
    }
  },
  "output": {
    "type": "json",
    "example": {
      "deal_activity": "Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.",
      "query_summary": {
        "as_of": "2026-06-07",
        "depth": "standard",
        "condition": "NASH (Nonalcoholic Steatohepatitis)"
      },
      "approved_drugs": [
        {
          "name": "Resmetirom (Rezdiffra)",
          "sponsor": "Madrigal Pharmaceuticals",
          "approved": "2024-03",
          "mechanism": "THR-β agonist",
          "indication": "NASH with moderate-to-advanced fibrosis"
        }
      ],
      "pdufa_calendar": [
        {
          "drug": "Lanifibranor",
          "sponsor": "Inventiva",
          "mechanism": "Pan-PPAR",
          "pdufa_estimate": "2026-Q1",
          "priority_review": false
        }
      ],
      "investment_thesis": "NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.",
      "opportunity_score": {
        "max": 100,
        "note": "Validated market with first approval. GLP-1 expansion threatening narrow competitors.",
        "score": 78,
        "rating": "High Value"
      },
      "pipeline_overview": {
        "phase2_count": 48,
        "phase3_count": 19,
        "total_active": 67,
        "approved_drugs": 2,
        "approval_recent_12m": 1
      },
      "top_phase3_assets": [
        {
          "drug": "Semaglutide 2.4mg",
          "nctId": "NCT04858633",
          "sponsor": "Novo Nordisk",
          "mechanism": "GLP-1 RA",
          "completion": "2025-Q4",
          "significance": "Blockbuster potential — NASH + obesity combined label"
        }
      ],
      "mechanism_landscape": {
        "crowded": [
          "FXR agonists (8 Phase 2/3)",
          "ACC inhibitors (6)",
          "FGF21 analogs (5)"
        ],
        "emerging": [
          "Pan-PPAR agonists",
          "GLP-1/GIP combinations (semaglutide expanding)"
        ],
        "opportunity_gaps": [
          "Cirrhosis reversal agents",
          "Pediatric NAFLD",
          "Combination sequential therapy protocols"
        ]
      },
      "key_readouts_next_18m": [
        "NASH-RESOLVE (semaglutide histology 2025)",
        "MAESTRO-NASH (lanifibranor 2025)",
        "ATLAS trial (aldafermin 2026)"
      ]
    }
  }
}